The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

Shutterstock photo

For Immediate Release

Chicago, IL -August 13, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo NordiskNVO , J&JJNJ , AllerganAGN , Editas Medicine, Inc.EDIT , AstraZenecaAZN , MerckMRK and Bristol-MyersBMY .

Here are highlights from Friday's Analyst Blog:

Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

After robust earnings performance by pharma bigwigs in the past couple of weeks, it was a relatively quiet period for the sector. Novo Nordisk beat estimates for both earnings and sales in the second quarter. J&J filed regulatory applications to get the label of its multiple myeloma drug, Darzalex updated to include a split dosing regimen. Allergan exercised its option to buy development/commercialization rights to Editas Medicine, Inc.'s lead CRISPR genome-editing ocular therapy, EDIT-101.

Recap of the Week's Most Important Stories

Novo Nordisk Q2 Earnings & Sales Beat : Novo Nordisk beat estimates for both earnings and sales in the second quarter. Earnings per American depositary receipt of 68 cents were higher than 59 cents earned in the year-ago period. Total revenues of $4.38 billion rose 2% in local currency. While sales in the Diabetes and Obesity Care segment rose 4% in local currency, the same in Biopharmaceuticals segment declined 4%.

J&J Seeks Approval for Split Dosing Regimen of Darzalex:  J&J filed regulatory applications in both the United States and EU for label expansion of its multiple myeloma drug, Darzalex. J&J is looking to get the label of Darzalex updated to allow prescribing the medicine by splitting the first infusion of Darzalex over two consecutive days. Approval for this split dosing option is likely to improve the administration profile of the medicine.

Allergan Buys Ocular Candidate from Editas:  Allergan exercised its option for the discovery and development of genome editing company Editas' lead CRISPR genome-editing ocular therapy, EDIT-101. It is being developed for Leber congenital amaurosis (LCA10), a rare, inherited retinal degenerative disease that appears in childhood and leads to blindness. For exercising the option, Allergan paid Editas a fee of $15 million per their deal in March last year. Allergan is now responsible for development and commercialization of EDIT-101.

AstraZeneca/Merck's Selumetinib Granted Orphan Designation in Europe:  AstraZeneca and partner Merck announced that their MEK 1/2 inhibitor, selumetinib has been granted orphan designation by the European Medicines Agency (EMA) for the treatment of neurofibromatosis type 1 (NF1), an incurable genetic condition that affects newborns. This designation is assigned to drugs, which are intended to treat rare disease.

In the past six months, Lilly has been the biggest gainer (34.0%) while Bristol-Myers declined the most (5.8%).

What's Next in the Pharma World?

Watch out for several pipeline and regulatory updates next week

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339



Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance  for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN): Free Stock Analysis Report

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Allergan plc (AGN): Free Stock Analysis Report

Novo Nordisk A/S (NVO): Free Stock Analysis Report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

Editas Medicine, Inc. (EDIT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Stocks
Referenced Symbols: AZN , BMY , AGN , NVO , JNJ

More from Zacks.com




Equity Research

Research Brokers before you trade

Want to trade FX?